Geode Capital Management
LSB

Geode Capital Management’s LakeShore Biopharma LSB Stock Holding History

Geode Capital Management’s Portfolio LSB Stock Details LSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,361
Closed -$8.82K – 4588
2024
Q2 		$8.82K Hold
1,361
– – ﹤0.01% 4553
2024
Q1 		$9.53K Hold
1,361
– – ﹤0.01% 4556
2023
Q4 		$7.32K Hold
1,361
– – ﹤0.01% 4613
2023
Q3 		$10.9K Hold
1,361
– – ﹤0.01% 4720
2023
Q2 		$18.8K Hold
1,361
– – ﹤0.01% 4664
2023
Q1 		$21.8K Buy
+1,361
New +$69K ﹤0.01% 4690

Other funds holding LSB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
SCM
Superstring Capital Management New York $158M AUM 418.32% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's LSB Position: Q3 2024 in Review

Geode Capital Management sold out of LakeShore Biopharma (LSB) in Q3 2024, closing a stake of 1,361 shares — an estimated $8.82K sold.

Geode Capital Management first reported a position in LSB in Q1 2023 and held it in 6 quarters. The position peaked at $21.8K in Q1 2023. 7 funds tracked by Wall St. Rank hold LSB as of Q3 2024.

  • Geode Capital Management reported no remaining LakeShore Biopharma position as of Q3 2024 after selling out during the quarter.
  • Geode Capital Management sold 1,361 LakeShore Biopharma shares in Q3 2024, an estimated $8.82K.
  • Geode Capital Management first reported a position in LakeShore Biopharma in Q1 2023 and held it in 6 quarters.
  • Geode Capital Management's LakeShore Biopharma position peaked at $21.8K in Q1 2023.
  • 7 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q3 2024.

Based on Geode Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.